Article
Diversity in Cancer Clinical Trials
“I think it’s important to ensure that you consider each person uniquely. Because no matter how much I know or the nurse knows about the population, everybody is a little bit different. It’s really important to personalize every approach and ask them what they know and meet them where they are,” ONS member Reneé Kurz, DNP, RN, FNP-BC, AOCNP®, director of clinical research operations at Rutgers Cancer Institute of New Jersey in New Brunswick, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS, during a conversation about increasing diversity in clinical trials.
Related Topics
You May Also Like
Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Article
Clinical Educator Oncology Program Improves Adherence by 29%
Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
Article